Lexeo Therapeutics (LXEO) Interest Expenses (2022 - 2026)
Lexeo Therapeutics (LXEO) posted Interest Expenses of $2.8 million for Q1 2026, up 32.88% sequentially from $2.1 million in Q4 2025, and up 417.82% YoY from $533000.0 in Q1 2025.
Lexeo Therapeutics (LXEO) Interest Expenses (2022 - 2026) Analysis & Trends
Lexeo Therapeutics has reported Interest Expenses for 5 years, with the latest figure at $2.8 million in Q1 2026.
- Quarterly Interest Expenses rose 417.82% year-over-year to $2.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.8 million (up 886.32% YoY) and the FY2025 annual result came in at $118.9 million, up 1790.26% from the prior year.
- Interest Expenses grew to $2.8 million in Q1 2026 per LXEO's latest filing, from $2.1 million in the prior quarter.
- Over five years, Interest Expenses peaked at $18.2 million in Q1 2024 and troughed at -$1.4 million in Q4 2024.
- A 5-year average of $4.9 million and a median of $2.1 million in 2025 frame the typical range for Interest Expenses.
- The widest YoY moves for Interest Expenses: up 3354.04% in 2024, down 2982.0% in 2024.
- Over 5 years, Interest Expenses stood at -$193000.0 in 2022, then jumped by 125.91% to $50000.0 in 2023, then tumbled by 2982.0% to -$1.4 million in 2024, then soared by 244.14% to $2.1 million in 2025, then surged by 32.88% to $2.8 million in 2026.
- According to Business Quant data, Interest Expenses over the past three periods registered $2.8 million, $2.1 million, and $8.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Lexeo Therapeutics | 397.10 Mn | 397.10 Mn | - | 7.07 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.07 Mn |
| Jun 30, 2026 | 7.07 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Mar 31, 2026 | 2.76 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Dec 31, 2025 | 2.08 Mn |
| Sep 30, 2025 | 8.70 Mn |
| Sep 30, 2025 | 8.70 Mn |
| Jun 30, 2025 | 9.24 Mn |
| Jun 30, 2025 | 9.24 Mn |
| Mar 31, 2025 | 533,000.00 |
| Mar 31, 2025 | 533,000.00 |
| Dec 31, 2024 | -1.44 Mn |
| Dec 31, 2024 | -1.44 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Sep 30, 2024 | 5.52 Mn |
| Jun 30, 2024 | 17.51 Mn |
| Jun 30, 2024 | 17.51 Mn |
| Mar 31, 2024 | 18.24 Mn |
| Mar 31, 2024 | 18.24 Mn |